The Department of Defense's Defense Health Agency awarded a $1,182,931 Project Grant to Duke University on February 1, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a 3-year project focused on "NK CELL RESPONSE AS A CLINICAL DIFFERENTIATOR OF ENDOCRINE THERAPIES" that will be conducted at Duke University's Office of Research Administration Division. This research aims to improve understanding of the clinical implications of natural killer (NK) cell responses to endocrine therapies, which may help differentiate the efficacy of various treatments. Through this grant, Duke University will provide critical biomedical research services to advance military medicine and improve health outcomes for service members, veterans, and their families.
Generated 10/29/24, 1:50 AM